McKesson (MCK)
(Delayed Data from NYSE)
$556.15 USD
-0.55 (-0.10%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $556.37 +0.22 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$556.15 USD
-0.55 (-0.10%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $556.37 +0.22 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $330.44, moving +0.8% from the previous trading session.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
McKesson (MCK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $327.81, marking a +0.37% move from the previous day.
Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.
Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome
by Zacks Equity Research
QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.
3 Medical Device Stocks With Potential to Fight Recession Risk
by Indrajit Bandyopadhyay
The decline in U.S. GDP during the first quarter and 26% decline in the S&P 500 Index so far this year fuel the risk of a recession. MCK, PDCO & AMN have the potential to help investors ward off volatility risks going forward.
NextGen (NXGN)-InstaMed Ink Deal to Improve Payment Processing
by Zacks Equity Research
NextGen's (NXGN) latest expanded deal with InstaMed is expected to significantly simplify payment methods for both patients and providers.
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care.
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Alcon's (ALC) Product Launches, Market Recovery Aid Growth
by Zacks Equity Research
Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.
McKesson (MCK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $330 in the latest trading session, marking a +1.08% move from the prior day.
3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
Has McKesson (MCK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Zacks Value Trader Highlights: H&R Block, McKesson, Stride, TransAlta and Murphy USA
by Zacks Equity Research
H&R Block, McKesson, Stride, TransAlta and Murphy USA are part of Zacks Value Trader blog.
5 Value Stocks Near Their 52-Week Highs
by Tracey Ryniec
Not every stock is selling off in 2022. Here are 5 cheap stocks with high Zacks Rank trading near their 52-week highs.
This Medical Supplier Is Pushing All-Time Highs
by Derek Lewis
McKesson shares have been scorching-hot year-to-date, increasing by more than 30% in value and extensively outperforming both its Zacks Sector and the S&P 500.
McKesson (MCK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $325.18, marking a -0.67% move from the previous day.
McKesson (MCK) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $321.25, moving -0.09% from the previous trading session.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG